MARC details
| 000 -LEADER |
|---|
| fixed length control field |
11636namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20250924111358.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
250827s2024 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
616.994347 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
616.994347 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.19.04.M.Sc.2024.Jo.E |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
John Ernest Botrous, |
| Preparation |
preparation. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Factors predicting recurrence after curative resection of rectal adenocarcinoma / |
| Statement of responsibility, etc. |
by John Ernest Botrous ; Supervised by Prof. Dr. Fouad Abdelshaheed Fouad, Dr. Sayed Mohamed Shaker Shaeir, Dr. Ayman Abdelhameed Mohamed Elhanafy. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
العوامل المسببه لتكرار الاصابه بعد الاستئصال العلاجي لسرطان المستقيم |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2024. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
118 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (Ph.D)-Cairo University, 2024. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 101-118. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
Background: <br/>Rectal cancer is the third most common cancer in the world, and its incidence is on the rise. Both the total mesorectal excision (TME) procedure and chemoradiation have improved survival. Five-year survival figures have increased up to 60 %, reaching the level of colon cancer survival <br/> Local recurrence manifests after rectal cancer operation in 2.4–10 % of patients, and one third of these are resectable. Distant metastases, especially in the liver and lungs, occur in 20–50 % of patients, and an increasing proportion of these can be treated with curative intent. Distant metastases reduce survival; thus, efforts should be directed to preventing systemic disease .<br/>Survival and disease-free survival in CRC has been related to many clinical, pathological, molecular, and genetic factors. This is why issues like early diagnosis, patient age, tumor location, histology, depth of invasion, lymph node invasion, levels of carcino-embriogenic antigen (CEA) and genetic expression gain importance when concerning evaluating prognosis.<br/> Above all this factors, pathological analysis of the surgical specimen is the most relevant information in order to establish prognosis.<br/>Concerning surgical technique, the one most important technical detail in rectal cancer surgery is total mesorectal excision (TME), whereas other concepts like high ligation of mesenteric vessels and lateral pelvic dissection remain object of frequent debate.<br/>Every healthcare professional dealing with rectal cancer treatment is still challenged by both local and metastatic recurrence which is by far the most import concern. It is responsible for a high morbidity and mortality. The best treatment that has also shown the best results in rectal cancer treatment includes neoadjuvant therapy when indicated, excision of rectum, together with mesorectum (TME), and adjuvant therapy, when needed<br/>Objectives:<br/>Identify the different prognostic factors affecting the local and nodal recurrence of rectal adenocarcinoma after curative resection.<br/>Patients and methods:<br/>a retrospective Cohort study which was conducted on all patients diagnosed with recurrent rectal cancer after curative resection and performed surgery at NCI from 2015 to 2019.<br/>Results:<br/>The age ranged from 27 to 74 years with a mean value (± SD) of 50.4 (±12.15) years. There were 29 (47.54%) males and 32 (52.46%) females. <br/>Location of tumor was upper in 11 (18.03%) patients, middle in 27 (44.26%) patients and lower in 23 (37.7%) patients. Tumor was AC in 53 (86.89%) patients, mucinus in 5 (8.2%) patients, GIST in 1 (1.64%) patient, intra mucosal ca in 1 (1.64%) and signet ring AC in 1 (1.64%) patient. Stage of tumor was Tcis N0M0 in 1 (1.64%) patient, T2N0M0 in 20 (32.79%) patients, T2N1M0 in 1 (1.64%) patient, T3N0M0 in 35 (57.38%) patients, T3N1M0 in 2 (3.28%) patients, T3N2M0 in 1 (1.64%) patient and T4N0M0 in 1 (1.64%) patient. Neo adjuvant was CRTH in 33 (54.1%) patients and CTH in 13 (21.31%) patients.<br/>Type of surgery was APR open in 24 (39.34%) patients, LAR open in 21 (34.43%) patients, LAR lap in 12 (19.67%) patients, LAR in 3 (4.92%) patients and end resection in 1 (1.64%) patient. Type of anastomosis was hand sewn in 36 (59.02%) patients and stappler in 24 (39.34%) patients. <br/>Type of pathology was AC in 55 (90.16%) patients, mucinus in 5 (8.2%) patients and GIST in 1 (1.64%) patient. Stage of tumor was T2N0M0 in 9 (14.75%) patients, T3N0M0 in 41 (67.21%) patients, T3NIM0 in 9 (14.75%) and T4N1M0 in 2 (3.28%) patients.<br/>PNI was positive in 20 (32.79%) patients. LVI was positive in 16 (26.23%) patients. Prostate was invasive organs in 2 (3.28%) patients. Invasion of pericolic fat was positive in 14 (22.95%) patients.<br/>SM was positive in Positive in 1 (1.64%) patient and Close in 5 (8.2%) patients. Grade of tumor was grade 2 in 54 (88.52%) patients, grade 3 in 4 (6.56%) patients and Grade 4 in 3 (4.92%) patients. Adjuvant was CTH in 33 (54.1%) patients and CTH and RTH in 3 (4.92%) patients.<br/>The positive LN ranged from 0 to 7 with a mean value (± SD) of 0.54 (±1.36) . The distal margin ranged from 0.5 to 13 cm with a mean value (± SD) of 5.37 (±3.48) cm.<br/>The type of recurrence was hepatic metastasis in 4 (6.56%) patients, peritoneal metastasis in 4 (6.56%) patients and local in 53 (86.89%) patients. Date of recurrence ranged from 0 to 62 months with a mean value (± SD) of 23.2 (±13.93) months. The mortality rate was 48 (78.69%) patients.<br/>Conclusion:<br/>Rectal cancer was commonly adenocarcinoma and located in the middle part of the T3N0M0 stage. The most performed surgery was low anterior resection, and the most common preoperative adjuvant therapy was CRTH while in postoperative was CTH. Local recurrence occurred in 86.89% of patients, hepatic metastasis in 6.56% and peritoneal metastasis in 6.56% with a mortality rate of 21.31%. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
الخلفيه العلمية والهدف من الدراسة:<br/>كان الهدف من هذه الدراسة هو تحديد العوامل التنبؤية المختلفة التي تؤثر على الانتكاس المحلي والعقدي لسرطان المستقيم بعد الاستئصال العلاجي<br/>طرق البحث:<br/>أُجريت هذه الدراسة الاستعادية على 61 مريضًا تتراوح أعمارهم بين 18 و75 عامًا، يعانون من سرطان المستقيم الذين خضعوا لاستئصال أمامي منخفض واستئصال أمامي منخفض للغاية واستئصال بطني شرجي. من 2015 حتى 2019<br/>النتائج: <br/>• تراوحت الأعمار بين 27 و74 عامًا بمتوسط 50.4 (±12.15) عامًا. كان هناك 29 (47.54%) ذكور و32 (52.46%) إناث.<br/>• كان موقع الورم أعلى في 11 (18.03%) مريضًا، ومتوسط في 27 (44.26%) مريضًا، وأسفل في 23 (37.7%) مريضًا. كان سرطان الغدة الدرقية في 53 (86.89%) مريضًا، ومخاطي في 5 (8.2%) مريضًا، وورم بطانة الجهاز الهضمي في 1 (1.64%) مريضًا، وسرطان داخل الغشاء في 1 (1.64%) ومعدل حلقي في 1 (1.64%).<br/>• كان مرحلة الورم Tcis N0M0 في 1 (1.64%) مريضًا، T2N0M0 في 20 (32.79%) مريضًا، T2N1M0 في 1 (1.64%) مريضًا، T3N0M0 في 35 (57.38%) مريضًا، T3N1M0 في 2 (3.28%) مريضًا، T3N2M0 في 1 (1.64%) مريضًا وT4N0M0 في 1 (1.64%) مريضًا. كان العلاج المساعد في 33 (54.1%) مريضًا و العلاج الكيميائي في 13 (21.31%) مريضًا.<br/>• نوع الجراحة كان استئصال بطني شرجي مفتوح في 24 (39.34%) مريضًا، واستئصال أمامي منخفض مفتوح في 21 (34.43%) مريضًا، واستئصال أمامي منخفض بالمنظار في 12 (19.67%) مريضًا، واستئصال أمامي منخفض في 3 (4.92%) مريضًا واستئصال نهائي في 1 (1.64%) مريضًا.<br/>• كان نوع التوصيل مخيط يدويًا في 36 (59.02%) مريضًا وتخييط آلي في 24 (39.34%) مريضًا.<br/>• كان نوع علم الأمراض الغدة الليمفاوية في 55 (90.16%) مريضًا، ومخاطي في 5 (8.2%) مريضًا و وورم بطانة الجهاز الهضمي في 1 (1.64%) مريضًا.<br/>• كان مرحلة الورم T2N0M0 في 9 (14.75%) مريضًا، وT3N0M0 في 41 (67.21%) مريضًا، وT3NIM0 في 9 (14.75%) وT4N1M0 في 2 (3.28%) مريضًا.<br/>• كانت الغزو العصبي إيجابيا في 20 (32.79%) مريضًا. كانت غزو الأوعية اللمفاوية إيجابيا في 16 (26.23%) مريضًا. كانت غزو البروستاتا للأعضاء الغازية في 2 (3.28%) مريضًا. كان غزو الدهون المحيطة بالأمعاء إيجابيًا في 14 (22.95%) مريضًا.<br/>• كانت كثرة الخلايا البدينة الجهازية إيجابية في 1 (1.64%) مريضًا وقريبة في 5 (8.2%) مريضًا. كانت درجة الورم 2 في 54 (88.52%) مريضًا، ودرجة 3 في 4 (6.56%) مريضًا ودرجة 4 في 3 (4.92%) مريضًا.<br/>• كانت العلاج المساعد للعلاج الكيميائي في 33 (54.1%) مريضًا والعلاج الكيميائي ومقاومة هرمون الغدة الدرقية في 3 (4.92%) مريضًا.<br/>• تراوحت العقد اللمفية الإيجابية من 0 إلى 7 بمتوسط 0.54 (±1.36).<br/>• تراوحت المسافة البعيدة من 0.5 إلى 13 سم بمتوسط 5.37 (±3.48) سم.<br/>• كان نوع الانتكاس نقائل كبدية في 4 (6.56%) مريضًا، ونقائل بطنية في 4 (6.56%) مريضًا وانتكاس محلي في 53 (86.89%) مريضًا. تراوحت مدة الانتكاس من 0 إلى 62 شهرًا بمتوسط 23.2 (±13.93) شهرًا. كانت نسبة الوفيات 48 (78.69%) مريضًا<br/>الاستنتاج:<br/> كان سرطان المستقيم غالبًا سرطان غدي ويقع في الجزء الأوسط من مرحلة T3N0M0. كانت الجراحة الأكثر إجراءً هي الاستئصال الأمامي المنخفض، وكان العلاج المساعد قبل الجراحة الأكثر شيوعًا هوالعلاج المساعد للعلاج الكيميائي بينما كان العلاج الكيميائي بعد الجراحة. حدث الانتكاس الموضعي في 86.89٪ من المرضى، ونقائل الكبد في 6.56٪ ونقائل الصفاق في 6.56٪ مع معدل وفيات 21.31٪ |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Rectal cancer |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
سرطان المستقيم |
| 653 #1 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Rectal cancer |
| -- |
recurrent rectal cancer |
| -- |
low anterior resection |
| -- |
neuro vascular invasion |
| -- |
lateral pelvic lymphadenectomy |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Fouad Abdelshaheed Fouad |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Sayed Mohamed Shaker Shaeir |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ayman Abdelhameed Mohamed Elhanafy |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2024 |
| Supervisory body |
Fouad Abdelshaheed Fouad |
| -- |
Sayed Mohamed Shaker Shaeir |
| -- |
Ayman Abdelhameed Mohamed Elhanafy |
| Universities |
Cairo University |
| Faculties |
National Cancer Institute |
| Department |
Department of Surgical oncology |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Shimaa |
| Reviser Names |
Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |